Is SARM1 a therapeutic target for ARSACS?- Dr. Thomas Schwarz

In Recherche 2019 by ARSACS

This project uses the sacsin mutant mouse and mice lacking SARM1 to ask whether the progression of the cell loss in ARSACS can be slowed or prevented by removing SARM1. A positive outcome would make ARSACS a strong candidate for this therapeutic strategy.

Duration : 18 months

Grant: $144,689


Dr. Thomas L. Schwarz, Professor, F.M. Kirby Neurobiology Center Children’s Hospital, Boston and Dept.of Neurobiology
Harvard Medical School CLSB 12-130, 3 Blackfan Street, Boston, MA 02115
Tel:(617)-919-2219 (office) or (617)-919-2264 (lab)

Interesting, right? Share with your friends & followers / Intéressant, non? Partagez avec vos amis: